Features of chronic hepatitis C in a patient with metabolic syndrome (clinical case)
https://doi.org/10.22627/2072-8107-2024-23-3-62-64
Abstract
Objective:To study the features of chronic hepatitis C in a 17-year-old patient with metabolic syndrome. Results: The article presents a clinical example of the course of chronic hepatitis C (HCV) in a 17-year-old patient with metabolic syndrome. He fell ill at the age of 13 and was seen by an infectious disease specialist. Antiviral therapy was not prescribed. A complete examination was conducted with an assessment of laboratory data. Biochemical activity, severity of liver fibrotic changes and signs of metabolic syndrome (MS) were compared. To assess the component composition of the body, a bioimpedance analysis was performed. Additionally, in order to identify associative links between gene polymorphism and MS components, the genetic profile of the patient and his parents was studied. Conclusion: A patient with genetic predictors of metabolic syndrome should be previously prescribed antiviral therapy for chronic hepatitis C.
About the Authors
A. A. Koklyushkina
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Yaroslavl.
M. S. Bokhonov
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Yaroslavl.
I. G. Sitnikov
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Yaroslavl.
V. L. Rozina
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Yaroslavl.
References
1. Healthcare in Russia. 2023: Statisticalcollection. Rosstat: M., 2023: З—46. (In Russ)
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 2002.
3. Zakharova I.N., S.I. Malyavskaya, T.M. Tvorogova, S.V. Vasilyeva, Yu.A. Dmitrieva, I.I. Pshenichnikova. Metabolic syndrome in children and adolescents. Meditsinskiy Sovet. 2016; 16:103—109. (In Russ)
4. Maleev V.V., Sitnikov I.G., Bokhonov M.S. Questions of hematology: a textbook. Еd. by V.V. Maleev. St. Petersburg: SpetsLit, 2016:367. (In Russ).
5. Anstee Q.M., Darlay R., Cockell S., Meroni M.et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. Journal of Hepatology. 2020; 73(3):505—515.
6. On the state of sanitary and epidemiological welfare of the population in the Yaroslavl region in 2022: State report. in the Yaroslavl region in 2022. 2023:38. (In Russ)
7. Bliznyuk S.A., Bubnova M.G., Yezhov M.V. Familial hypercholesterolemia: the current state of the problem and therapeutic and preventive care. Cardiovascular Тherapy and Рrevention. 2020; 19(5):2532.
8. Ferreira LD, Pulawa LK, Jensen DR, Eckel RH. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes. 2001 May; 50(5):1064—8. doi: 10.2337/diabetes.50.5.1064.
9. Loos RJ, Yeo GS (January 2014). «The bigger picture of FTO: the first GWAS-identified obesity gene». Nature Reviews. Endocrinology. 2014 Jan. 10(1):51—61. DOI: 10.1038/nrendo.2013.227
10. Mackness B, Beltran-Debon R, Aragones G, Joven J, Camps J, Mackness M. Human tissue distribution of paraoxonases 1 and 2 mRNA. IUBMB Life. 2010 Jun; 62(6):480—2. doi: 10.1002/iub.347.
11. Khetarpal SA, Zeng X, Millar JS, Vitali C. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med. 2017 Sep; 23(9):1086—1094. doi: 10.1038/nm.4390.
12. Karackattu SL, Trigatti B, Krieger M. Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SR-BI/apolipoprotein E double knockout mice. Arterioscler Thromb Vasc Biol. 2006 Mar; 26(3):548—54. doi: 10.1161/01.ATV.0000202662.63876.02.
Review
For citations:
Koklyushkina A.A., Bokhonov M.S., Sitnikov I.G., Rozina V.L. Features of chronic hepatitis C in a patient with metabolic syndrome (clinical case). CHILDREN INFECTIONS. 2024;23(3):62-64. (In Russ.) https://doi.org/10.22627/2072-8107-2024-23-3-62-64
Views:
337
Email this article 